Show simple item record

dc.contributor.authorDemetri, G
dc.contributor.authorReichardt, P
dc.contributor.authorKang, Y
dc.contributor.authorBlay, J
dc.contributor.authorRutkowski, P
dc.contributor.authorGelderblom, H
dc.contributor.authorHohenberger, P
dc.contributor.authorLeahy, Michael G
dc.contributor.authorvon Mehren, M
dc.contributor.authorJoensuu, H
dc.contributor.authorBadalamenti, G
dc.contributor.authorBlackstein, M
dc.contributor.authorLe Cesne, A
dc.contributor.authorSchöffski, P
dc.contributor.authorMaki, R
dc.contributor.authorBauer, S
dc.contributor.authorNguyen, B
dc.contributor.authorXu, J
dc.contributor.authorNishida, T
dc.contributor.authorChung, J
dc.contributor.authorKappeler, C
dc.contributor.authorKuss, I
dc.contributor.authorLaurent, D
dc.contributor.authorCasali, P
dc.date.accessioned2013-03-15T16:47:22Z
dc.date.available2013-03-15T16:47:22Z
dc.date.issued2013-01-26
dc.identifier.citationEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. 2013, 381 (9863):295-302 Lanceten_GB
dc.identifier.issn1474-547X
dc.identifier.pmid23177515
dc.identifier.doi10.1016/S0140-6736(12)61857-1
dc.identifier.urihttp://hdl.handle.net/10541/273028
dc.description.abstractUntil now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.
dc.language.isoenen
dc.rightsArchived with thanks to Lanceten_GB
dc.subject.meshAged
dc.subject.meshAntineoplastic Agents
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshGastrointestinal Neoplasms
dc.subject.meshGastrointestinal Stromal Tumors
dc.subject.meshHumans
dc.subject.meshIndoles
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPhenylurea Compounds
dc.subject.meshPiperazines
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshPyridines
dc.subject.meshPyrimidines
dc.subject.meshPyrroles
dc.subject.meshSurvival Rate
dc.subject.meshTreatment Failure
dc.titleEfficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.en
dc.typeArticleen
dc.contributor.departmentLudwig Center at Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.en_GB
dc.identifier.journalLanceten_GB
html.description.abstractUntil now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib.


Files in this item

This item appears in the following Collection(s)

Show simple item record